Could you give us a brief description of your start-up and explain the reasons that led you to establish it up?
Aptus.AI was born in 2018 from an idea of Andrea Tesei and Lorenzo De Mattei, with the aim of supporting companies in the process of implementing Artificial Intelligence, after having personally experienced the difficulties found by companies in adopting the technologies and hire the competences needed to fully exploit AI.
The original idea was therefore to create a startup able to provide proprietary technology products and support companies in their adoption. After 2 years of significant growth we focused our business on two markets, RegTech (from “Regulatory” and “Technology”) and MedTech. In MedTech, we are focusing on AI applied to radiology workflows and imaging, supporting the radiologist in the early diagnosis of breast cancer by applying Image Recognition and Deep Neural Networks to detect cancer through mammography screening.
The early diagnosis of breast cancer is now very widespread. How does your product intervene in the diagnosis process and what benefits does it bring?
Breast cancer is the most common type of cancer among women, accounting for 25% of all cancers. One in eight women develops breast cancer. Prevention and early diagnosis are the only possible cures today. Hence, an early diagnosis with Digital Imaging is essential: mammography screening has therefore become a regular practice, also supported by Health Systems. DeepMammo is the Artificial Intelligence tool for the early screening of breast cancer, which helps the radiologist in his daily work. DeepMammo supports imaging workflows by increasing radiologist performance, reducing diagnostic errors, decreasing workloads and, therefore, improving clinical practice and decreasing costs.
Finally, by reducing cancer screening time and providing a personalized method for it, we simplify and accelerate daily radiologist activities.
